Median progression-free survival was significantly longer with lenalidomide maintenance than with no maintenance ( @ months vs. @ months ; hazard ratio for progression or death , @ ; @ % CI , @ to @ ; P < @ ) , but @-year overall survival was not significantly prolonged ( @ % vs. @ % ; hazard ratio for death , @ ; @ % CI , @ to @ ; P = @ ) .